Avenue Therapeutics Inc ATXI:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 3:14 PM EDT
4.50quote price arrow up+0.30 (+7.14%)
Volume
187,273
52 week range
4.04 - 93.75
Loading...
  • Open4.15
  • Day High4.72
  • Day Low4.15
  • Prev Close4.20
  • 52 Week High93.75
  • 52 Week High Date07/14/23
  • 52 Week Low4.04
  • 52 Week Low Date05/07/24

Key Stats

  • Market Cap2.656M
  • Shares Out590,139.99
  • 10 Day Average Volume0.24M
  • Dividend-
  • Dividend Yield-
  • Beta-0.07
  • YTD % Change-62.57

KEY STATS

  • Open4.15
  • Day High4.72
  • Day Low4.15
  • Prev Close4.20
  • 52 Week High93.75
  • 52 Week High Date07/14/23
  • 52 Week Low4.04
  • 52 Week Low Date05/07/24
  • Market Cap2.656M
  • Shares Out590,139.99
  • 10 Day Average Volume0.24M
  • Dividend-
  • Dividend Yield-
  • Beta-0.07
  • YTD % Change-62.57

RATIOS/PROFITABILITY

  • EPS (TTM)-132.88
  • P/E (TTM)-0.03
  • Fwd P/E (NTM)-0.14
  • EBITDA (TTM)-14.539M
  • ROE (TTM)-378.24%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/10/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Avenue Therapeutics Inc

 

Profile

MORE
Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. The Company is developing three assets including AJ201, an asset for spinal and bulbar muscular atrophy; BAER-101, an oral small molecule selective Gamma-aminobutyric acid receptor A alpha 2 & 3 (GABAA α2, α3) receptor positive allosteric modulator for central nervous system (CNS) diseases; and IV tramadol...
Jay Kranzler M.D., Ph.D.
Non-Executive Chairman of the Board
Alexandra Maclean M.D.
Chief Executive Officer, Director
David Jin
Interim Chief Financial Officer, Chief Operating Officer
Address
1111 KANE CONCOURSE, SUITE 301
Bay Harbor Islands, FL
33154
United States